Fosravuconazole L-lysine ethanolate-武汉科斯坦生物科技有限公司

产品展厅

您当前的位置：网站首页 > 产品展厅 >小分子化合物 >Fosravuconazole L-lysine ethanolate

Fosravuconazole L-lysine ethanolate

英文名称：Fosravuconazole L-lysine ethanolate

品牌：Chemstan

产地：中国

货号：CS-16779B

cas：914361-45-8

价格： ￥3000/mg
发布日期： 2021-03-10
更新日期： 2025-09-19

发送咨询信息

产品详请

产地	中国
品牌	Chemstan
货号	CS-16779B
用途	科研
英文名称	Fosravuconazole L-lysine ethanolate
包装规格	5 mg
纯度	98.00%%
CAS编号	914361-45-8
别名
分子式
是否进口	否

Description

Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate), a prodrug of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole L-lysine ethanolate can be used for candidiasis, onychomycosis and parasitemia research^[1]^[2]^[3].

In Vitro

Fosravuconazole has potent in vitro antifungal activity against a wide range of fungal species, including Candida, Aspergillus, and Trichophyton species^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Fosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) treatment suppresses the parasitemia and prevents death in mice infected with the T. cruzi Y strain^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Swiss female mice (20-24 g) inoculated with trypomastigotes (Y strain)^[3].
Dosage:	10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg
Administration:	Oral administration; daily; for 20 days
Result:	Suppressed the parasitemia and prevented death.

Molecular Weight

739.73

Formula

C??H??F?N?O?PS

CAS No.

914361-45-8

SMILES

N#CC1=CC=C(C2=CSC([C@H](C)[C@@](OCOP(O)(O)=O)(C3=CC=C(F)C=C3F)CN4N=CN=C4)=N2)C=C1.CCO.N[C@H](C(O)=O)CCCCN

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (67.59 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (ultrasonic) (insoluble)

Preparing
Stock Solutions

ConcentrationSolventMass	1 mg	5 mg	10 mg

1 mM	1.3518 mL	6.7592 mL	13.5184 mL
5 mM	0.2704 mL	1.3518 mL	2.7037 mL
10 mM	0.1352 mL	0.6759 mL	1.3518 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution

*以上所有助溶剂都可在 MCE 网站选购。

References

[1]. Shinichi Watanabe, et al. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. J Dermatol. 2018 Oct;45(10):1151-1159.

[2]. Katsura Hata, et al. Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases. Parasitol Int. 2020 Dec 25;81:102278.

[3]. Lívia de Figueiredo Diniz, et al. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice. Antimicrob Agents Chemother. 2018 May 25;62(6):e00401-18.